Attention! Your ePaper is waiting for publication!
By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePaper readers on YUMPU.
This will ensure high visibility and many readers!
Your ePaper is now published and live on YUMPU!
You can find your publication here:
Share your interactive ePaper on all platforms and on your website with our embed function
BNF for Children 2011-2012
BNF for Children 2011-2012
BNF for Children 2011-2012
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>BNF</strong>C <strong>2011</strong>–<strong>2012</strong> 5.5.8 Drugs <strong>for</strong> strongyloidiasis 3475.5.8 Drugs <strong>for</strong> strongyloidiasisAdult <strong>for</strong>ms of Strongyloides stercoralis live in the gutand produce larvae which penetrate the gut wall andinvade the tissues, setting up a cycle of auto-infection.Ivermectin [unlicensed] in a dose of 200 micrograms/kg daily <strong>for</strong> 2 days is the treatment of choice <strong>for</strong> chronicStrongyloides infection in children over 5 years.Albendazole [unlicensed] is an alternative in childrenover 2 years given in a dose of 400 mg twice daily <strong>for</strong> 3days, repeated after 3 weeks if necessary.Both of these drugs are available from ‘special-order’manufacturers or specialist importing companies, seep. 809.5 Infections
346 5.5.4 Drugs <strong>for</strong> hookworms <strong>BNF</strong>C <strong>2011</strong>–<strong>2012</strong>gastro-intestinal upset, lightheadedness, and pruritus; itis not effective against larval worms. Fears of developingcysticercosis in Taenia solium infections haveproved unfounded. All the same, an antiemetic can begiven be<strong>for</strong>e treatment and a laxative can be given 2hours after niclosamide.Praziquantel [unlicensed] is available from Merck Serono(Cysticide c ); it is as effective as niclosamide and isgiven to children over 4 years of age as a single dose of5–10 mg/kg after a light breakfast (or as a single dose of25 mg/kg <strong>for</strong> Hymenolepis nana).Praziquantel [unlicensed] is available from Merck Serono(Cysticide c ) and is effective against all humanschistosomes. In children over 4 years the dose is20 mg/kg followed after 4–6 hours by a further dose of20 mg/kg (20 mg/kg 3 times daily <strong>for</strong> one day <strong>for</strong> S.japonicum infections). No serious adverse effects havebeen reported. Of all the available schistosomicides, ithas the most attractive combination of effectiveness,broad-spectrum activity, and low toxicity.5 InfectionsHydatid diseaseCysts caused by Echinococcus granulosus grow slowlyand asymptomatic children do not always require treatment.Surgical treatment remains the method of choicein many situations. Albendazole [unlicensed] (availablefrom ‘special-order’ manufacturers or specialist importingcompanies, see p. 809 is used in conjunction withsurgery to reduce the risk of recurrence or as primarytreatment in inoperable cases. Albendazole is given tochildren over 2 years of age in a dose of 7.5 mg/kg twicedaily (max. 400 mg twice daily) <strong>for</strong> 28 days followed by14-day break and then repeated <strong>for</strong> up to 2–3 cycles.Alveolar echinococcosis due to E. multilocularis isusually fatal if untreated. Surgical removal with albendazolecover is the treatment of choice, but where effectivesurgery is impossible, repeated cycles of albendazole(<strong>for</strong> a year or more) may help. Careful monitoringof liver function is particularly important during drugtreatment.5.5.4 Drugs <strong>for</strong> hookworms(ancylostomiasis, necatoriasis)Hookworms live in the upper small intestine and drawblood from the point of their attachment to their host.An iron-deficiency anaemia may occur and, if present,effective treatment of the infection requires not onlyexpulsion of the worms but treatment of the anaemia.Mebendazole (section 5.5.1) has a useful broad-spectrumactivity, and is effective against hookworms.Albendazole [unlicensed] (available from ‘specialorder’manufacturers or specialist importing companies,see p. 809) given as a single dose of 400 mg in childrenover 2 years, is an alternative. Levamisole is alsoeffective (section 5.5.2).5.5.5 Schistosomicides(bilharziasis)Adult Schistosoma haematobium worms live in thegenito-urinary veins and adult S. mansoni in those ofthe colon and mesentery. S. japonicum is more widelydistributed in veins of the alimentary tract and portalsystem.5.5.6 FilaricidesDiethylcarbamazine [unlicensed] (available from ‘special-order’manufacturers or specialist importing companies,see p. 809) is effective against microfilariae andadult worms of Loa loa, Wuchereria bancrofti, andBrugia malayi. To minimise reactions, treatment inchildren over 1 month is commenced with a dose ofdiethylcarbamazine citrate 1 mg/kg in divided doses onthe first day and increased gradually over 3 days to6 mg/kg daily (3 mg/kg daily if child under 10 years) individed doses; length of treatment varies according toinfection type, and usually gives a radical cure <strong>for</strong> theseinfections. Close medical supervision is necessary particularlyin the early phase of treatment. In heavy infectionsthere may be a febrile reaction, and in heavy Loaloa infection there is a small risk of encephalopathy. Insuch cases specialist advice should be sought, andtreatment must be given under careful in-patient supervisionand stopped at the first sign of cerebral involvement.Ivermectin [unlicensed] (available from ‘special-order’manufacturers or specialist importing companies, seep. 809) is very effective in onchocerciasis and it is nowthe drug of choice. In children over 5 years, a singledose of 150 micrograms/kg by mouth produces a prolongedreduction in microfilarial levels. Retreatment atintervals of 6 to 12 months depending on symptomsmust be given until the adult worms die out. Reactionsare usually slight and most commonly take the <strong>for</strong>m oftemporary aggravation of itching and rash. Diethylcarbamazineor suramin should no longer be used <strong>for</strong>onchocerciasis because of their toxicity.5.5.7 Drugs <strong>for</strong> cutaneous larvamigrans(creeping eruption)Dog and cat hookworm larvae may enter human skinwhere they produce slowly extending itching tracksusually on the foot. Single tracks can be treated withtopical tiabendazole (no commercial preparation available).Multiple infections respond to ivermectin,albendazole or tiabendazole (thiabendazole) bymouth (all unlicensed and available from ‘specialorder’manufacturers or specialist importing companies,see p. 809).
<strong>BNF</strong>C <strong>2011</strong>–<strong>2012</strong> 5.5.8 Drugs <strong>for</strong> strongyloidiasis 3475.5.8 Drugs <strong>for</strong> strongyloidiasisAdult <strong>for</strong>ms of Strongyloides stercoralis live in the gutand produce larvae which penetrate the gut wall andinvade the tissues, setting up a cycle of auto-infection.Ivermectin [unlicensed] in a dose of 200 micrograms/kg daily <strong>for</strong> 2 days is the treatment of choice <strong>for</strong> chronicStrongyloides infection in children over 5 years.Albendazole [unlicensed] is an alternative in childrenover 2 years given in a dose of 400 mg twice daily <strong>for</strong> 3days, repeated after 3 weeks if necessary.Both of these drugs are available from ‘special-order’manufacturers or specialist importing companies, seep. 809.5 Infections
- Page 2 and 3:
Medicines information servicesInfor
- Page 4 and 5:
Published byBMJ GroupTavistock Squa
- Page 6 and 7:
iv BNFC 2011-2012PrefaceBNF for Chi
- Page 8 and 9:
vi BNFC 2011-2012BNF StaffDigital D
- Page 10 and 11:
viii BNFC 2011-2012Nurse Prescriber
- Page 12 and 13:
x BNFC 2011-2012. incorporating the
- Page 14 and 15:
xii BNFC 2011-2012prescribing notes
- Page 16 and 17:
Branded oral liquid preparations th
- Page 18 and 19:
xvi BNFC 2011-2012Finding significa
- Page 20 and 21:
xviii BNFC 2011-2012Epilim Chronosp
- Page 22 and 23:
xx BNFC 2011-2012Tears Naturale c S
- Page 24 and 25:
2 General guidance BNFC 2011-2012Ge
- Page 26 and 27:
4 Prescription writing BNFC 2011-20
- Page 28 and 29:
6 Supply of medicines BNFC 2011-201
- Page 30 and 31:
8 Emergency supply of medicines BNF
- Page 32 and 33:
10 Prescribing Controlled Drugs BNF
- Page 34 and 35:
Adverse reactions to drugs12 Advers
- Page 36 and 37:
Prescribing in hepatic impairment14
- Page 38 and 39:
Prescribing in pregnancy16 Prescrib
- Page 40 and 41:
18 Prescribing in palliative care B
- Page 42 and 43:
20 Prescribing in palliative care B
- Page 44 and 45:
22 Prescribing in dental practice B
- Page 46 and 47:
Emergency treatment of poisoning24
- Page 48 and 49:
26 Emergency treatment of poisoning
- Page 50 and 51:
28 Emergency treatment of poisoning
- Page 52 and 53:
30 Emergency treatment of poisoning
- Page 54 and 55:
32 Emergency treatment of poisoning
- Page 56 and 57:
34 Emergency treatment of poisoning
- Page 58 and 59:
36 1.1.1 Antacids and simeticone BN
- Page 60 and 61:
38 1.1.2 Compound alginate preparat
- Page 62 and 63:
40 1.2 Antispasmodics and other dru
- Page 64 and 65:
42 1.3 Antisecretory drugs and muco
- Page 66 and 67:
44 1.3.3 Chelates and complexes BNF
- Page 68 and 69:
46 1.4 Acute diarrhoea BNFC 2011-20
- Page 70 and 71:
48 1.5 Chronic bowel disorders BNFC
- Page 72 and 73:
50 1.5.1 Aminosalicylates BNFC 2011
- Page 74 and 75:
52 1.5.1 Aminosalicylates BNFC 2011
- Page 76 and 77:
54 1.5.3 Drugs affecting the immune
- Page 78 and 79:
56 1.5.4 Food allergy BNFC 2011-201
- Page 80 and 81:
58 1.6.1 Bulk-forming laxatives BNF
- Page 82 and 83:
60 1.6.2 Stimulant laxatives BNFC 2
- Page 84 and 85:
62 1.6.4 Osmotic laxatives BNFC 201
- Page 86 and 87:
64 1.6.5 Bowel cleansing preparatio
- Page 88 and 89:
66 1.7 Local preparations for anal
- Page 90 and 91:
68 1.8 Stoma and enteral feeding tu
- Page 92 and 93:
70 1.9.2 Bile acid sequestrants BNF
- Page 94 and 95:
72 1.9.4 Pancreatin BNFC 2011-20121
- Page 96 and 97:
74 2.1.1 Cardiac glycosides BNFC 20
- Page 98 and 99:
76 2.2 Diuretics BNFC 2011-20122 Ca
- Page 100 and 101:
78 2.2.2 Loop diuretics BNFC 2011-2
- Page 103 and 104:
BNFC 2011-2012 2.2.4 Potassium-spar
- Page 105 and 106:
BNFC 2011-2012 2.3.2 Drugs for arrh
- Page 107 and 108:
BNFC 2011-2012 2.3.2 Drugs for arrh
- Page 109 and 110:
BNFC 2011-2012 2.4 Beta-adrenocepto
- Page 111 and 112:
BNFC 2011-2012 2.4 Beta-adrenocepto
- Page 113 and 114:
BNFC 2011-2012 2.4 Beta-adrenocepto
- Page 115 and 116:
BNFC 2011-2012 2.5.1 Vasodilator an
- Page 117 and 118:
BNFC 2011-2012 2.5.1 Vasodilator an
- Page 119 and 120:
BNFC 2011-2012 2.5.1 Vasodilator an
- Page 121 and 122:
BNFC 2011-2012 2.5.4 Alpha-adrenoce
- Page 123 and 124:
BNFC 2011-2012 2.5.5 Drugs affectin
- Page 125 and 126:
BNFC 2011-2012 2.5.5 Drugs affectin
- Page 127 and 128:
BNFC 2011-2012 2.6.2 Calcium-channe
- Page 129 and 130:
BNFC 2011-2012 2.6.2 Calcium-channe
- Page 131 and 132:
BNFC 2011-2012 2.6.2 Calcium-channe
- Page 133 and 134:
BNFC 2011-2012 2.7.1 Inotropic symp
- Page 135 and 136:
BNFC 2011-2012 2.7.2 Vasoconstricto
- Page 137 and 138:
BNFC 2011-2012 2.8.1 Parenteral ant
- Page 139 and 140:
BNFC 2011-2012 2.8.1 Parenteral ant
- Page 141 and 142:
BNFC 2011-2012 2.8.2 Oral anticoagu
- Page 143 and 144:
BNFC 2011-2012 2.10 Myocardial infa
- Page 145 and 146:
BNFC 2011-2012 2.11 Antifibrinolyti
- Page 147 and 148:
BNFC 2011-2012 2.12 Lipid-regulatin
- Page 149 and 150:
BNFC 2011-2012 2.12 Lipid-regulatin
- Page 151 and 152:
BNFC 2011-2012 2.12 Lipid-regulatin
- Page 153 and 154:
BNFC 2011-2012 2.14 Drugs affecting
- Page 155 and 156:
BNFC 2011-2012 1333 Respiratory sys
- Page 157 and 158:
BNFC 2011-2012 3.1 Bronchodilators
- Page 159 and 160:
BNFC 2011-2012 3.1.1 Adrenoceptor a
- Page 161 and 162:
BNFC 2011-2012 3.1.1 Adrenoceptor a
- Page 163 and 164:
BNFC 2011-2012 3.1.2 Antimuscarinic
- Page 165 and 166:
BNFC 2011-2012 3.1.3 Theophylline 1
- Page 167 and 168:
BNFC 2011-2012 3.1.5 Peak flow mete
- Page 169 and 170:
BNFC 2011-2012 3.2 Corticosteroids
- Page 171 and 172:
BNFC 2011-2012 3.2 Corticosteroids
- Page 173 and 174:
BNFC 2011-2012 3.3 Cromoglicate and
- Page 175 and 176:
BNFC 2011-2012 3.4 Antihistamines,
- Page 177 and 178:
BNFC 2011-2012 3.4.1 Antihistamines
- Page 179 and 180:
BNFC 2011-2012 3.4.2 Allergen immun
- Page 181 and 182:
BNFC 2011-2012 3.4.3 Allergic emerg
- Page 183 and 184:
BNFC 2011-2012 3.4.3 Allergic emerg
- Page 185 and 186:
BNFC 2011-2012 3.6 Oxygen 163ment
- Page 187 and 188:
BNFC 2011-2012 3.7 Mucolytics 165HO
- Page 189 and 190:
BNFC 2011-2012 3.9 Cough preparatio
- Page 191 and 192:
BNFC 2011-2012 1694 Central nervous
- Page 193 and 194:
BNFC 2011-2012 4.1.2 Anxiolytics 17
- Page 195 and 196:
BNFC 2011-2012 4.2.1 Antipsychotic
- Page 197 and 198:
BNFC 2011-2012 4.2.1 Antipsychotic
- Page 199 and 200:
BNFC 2011-2012 4.2.1 Antipsychotic
- Page 201 and 202:
BNFC 2011-2012 4.2.1 Antipsychotic
- Page 203 and 204:
BNFC 2011-2012 4.2.2 Antipsychotic
- Page 205 and 206:
BNFC 2011-2012 4.3 Antidepressant d
- Page 207 and 208:
BNFC 2011-2012 4.3.1 Tricyclic anti
- Page 209 and 210:
BNFC 2011-2012 4.3.3 Selective sero
- Page 211 and 212:
BNFC 2011-2012 4.4 CNS stimulants a
- Page 213 and 214:
BNFC 2011-2012 4.5 Drugs used in th
- Page 215 and 216:
BNFC 2011-2012 4.6 Drugs used in na
- Page 217 and 218:
BNFC 2011-2012 4.6 Drugs used in na
- Page 219 and 220:
BNFC 2011-2012 4.6 Drugs used in na
- Page 221 and 222:
BNFC 2011-2012 4.7 Analgesics 199Sc
- Page 223 and 224:
BNFC 2011-2012 4.7.1 Non-opioid ana
- Page 225 and 226:
BNFC 2011-2012 4.7.2 Opioid analges
- Page 227 and 228:
BNFC 2011-2012 4.7.2 Opioid analges
- Page 229 and 230:
BNFC 2011-2012 4.7.2 Opioid analges
- Page 231 and 232:
BNFC 2011-2012 4.7.2 Opioid analges
- Page 233 and 234:
BNFC 2011-2012 4.7.2 Opioid analges
- Page 235 and 236:
BNFC 2011-2012 4.7.4 Antimigraine d
- Page 237 and 238:
BNFC 2011-2012 4.8 Antiepileptics 2
- Page 239 and 240:
BNFC 2011-2012 4.8.1 Control of the
- Page 241 and 242:
BNFC 2011-2012 4.8.1 Control of the
- Page 243 and 244:
BNFC 2011-2012 4.8.1 Control of the
- Page 245 and 246:
BNFC 2011-2012 4.8.1 Control of the
- Page 247 and 248:
BNFC 2011-2012 4.8.1 Control of the
- Page 249 and 250:
BNFC 2011-2012 4.8.1 Control of the
- Page 251 and 252:
BNFC 2011-2012 4.8.1 Control of the
- Page 253 and 254:
BNFC 2011-2012 4.8.2 Drugs used in
- Page 255 and 256:
BNFC 2011-2012 4.8.2 Drugs used in
- Page 257 and 258:
BNFC 2011-2012 4.8.3 Febrile convul
- Page 259 and 260:
BNFC 2011-2012 4.9.2 Antimuscarinic
- Page 261 and 262:
BNFC 2011-2012 4.10.2 Nicotine depe
- Page 263 and 264:
BNFC 2011-2012 4.10.2 Nicotine depe
- Page 265 and 266:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 267 and 268:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 269 and 270:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 271 and 272:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 273 and 274:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 275 and 276:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 277 and 278:
BNFC 2011-2012 5.1 Antibacterial dr
- Page 279 and 280:
BNFC 2011-2012 5.1.1 Penicillins 25
- Page 281 and 282:
BNFC 2011-2012 5.1.1 Penicillins 25
- Page 283 and 284:
BNFC 2011-2012 5.1.1 Penicillins 26
- Page 285 and 286:
BNFC 2011-2012 5.1.1 Penicillins 26
- Page 287 and 288:
BNFC 2011-2012 5.1.1 Penicillins 26
- Page 289 and 290:
BNFC 2011-2012 5.1.2 Cephalosporins
- Page 291 and 292:
BNFC 2011-2012 5.1.2 Cephalosporins
- Page 293 and 294:
BNFC 2011-2012 5.1.2 Cephalosporins
- Page 295 and 296:
BNFC 2011-2012 5.1.2 Cephalosporins
- Page 297 and 298:
BNFC 2011-2012 5.1.3 Tetracyclines
- Page 299 and 300:
BNFC 2011-2012 5.1.4 Aminoglycoside
- Page 301 and 302:
BNFC 2011-2012 5.1.4 Aminoglycoside
- Page 303 and 304:
BNFC 2011-2012 5.1.5 Macrolides 281
- Page 305 and 306:
BNFC 2011-2012 5.1.6 Clindamycin 28
- Page 307 and 308:
BNFC 2011-2012 5.1.7 Some other ant
- Page 309 and 310:
BNFC 2011-2012 5.1.7 Some other ant
- Page 311 and 312:
BNFC 2011-2012 5.1.8 Sulfonamides a
- Page 313 and 314:
BNFC 2011-2012 5.1.9 Antituberculos
- Page 315 and 316:
BNFC 2011-2012 5.1.9 Antituberculos
- Page 317 and 318: BNFC 2011-2012 5.1.11 Metronidazole
- Page 319 and 320: BNFC 2011-2012 5.1.12 Quinolones 29
- Page 321 and 322: BNFC 2011-2012 5.1.13 Urinary-tract
- Page 323 and 324: BNFC 2011-2012 5.2.1 Triazole antif
- Page 325 and 326: BNFC 2011-2012 5.2.1 Triazole antif
- Page 327 and 328: BNFC 2011-2012 5.2.2 Imidazole anti
- Page 329 and 330: BNFC 2011-2012 5.2.4 Echinocandin a
- Page 331 and 332: BNFC 2011-2012 5.3 Antiviral drugs
- Page 333 and 334: BNFC 2011-2012 5.3.1 HIV infection
- Page 335 and 336: BNFC 2011-2012 5.3.1 HIV infection
- Page 337 and 338: BNFC 2011-2012 5.3.1 HIV infection
- Page 339 and 340: BNFC 2011-2012 5.3.1 HIV infection
- Page 341 and 342: BNFC 2011-2012 5.3.1 HIV infection
- Page 343 and 344: BNFC 2011-2012 5.3.2 Herpesvirus in
- Page 345 and 346: BNFC 2011-2012 5.3.2 Herpesvirus in
- Page 347 and 348: BNFC 2011-2012 5.3.3 Viral hepatiti
- Page 349 and 350: BNFC 2011-2012 5.3.5 Respiratory sy
- Page 351 and 352: BNFC 2011-2012 5.4 Antiprotozoal dr
- Page 353 and 354: BNFC 2011-2012 5.4.1 Antimalarials
- Page 355 and 356: BNFC 2011-2012 5.4.1 Antimalarials
- Page 357 and 358: BNFC 2011-2012 5.4.1 Antimalarials
- Page 359 and 360: BNFC 2011-2012 5.4.1 Antimalarials
- Page 361 and 362: BNFC 2011-2012 5.4.2 Amoebicides 33
- Page 363 and 364: BNFC 2011-2012 5.4.6 Trypanocides 3
- Page 365 and 366: BNFC 2011-2012 5.4.8 Drugs for pneu
- Page 367: BNFC 2011-2012 5.5.2 Ascaricides 34
- Page 371 and 372: BNFC 2011-2012 6.1.1 Insulins 349Tr
- Page 373 and 374: BNFC 2011-2012 6.1.1 Insulins 351So
- Page 375 and 376: BNFC 2011-2012 6.1.1 Insulins 353IN
- Page 377 and 378: BNFC 2011-2012 6.1.1 Insulins 355Hi
- Page 379 and 380: BNFC 2011-2012 6.1.2 Antidiabetic d
- Page 381 and 382: BNFC 2011-2012 6.1.2 Antidiabetic d
- Page 383 and 384: BNFC 2011-2012 6.1.4 Treatment of h
- Page 385 and 386: BNFC 2011-2012 6.1.6 Diagnostic and
- Page 387 and 388: BNFC 2011-2012 6.2 Thyroid and anti
- Page 389 and 390: BNFC 2011-2012 6.2.2 Antithyroid dr
- Page 391 and 392: BNFC 2011-2012 6.3 Corticosteroids
- Page 393 and 394: BNFC 2011-2012 6.3.2 Glucocorticoid
- Page 395 and 396: BNFC 2011-2012 6.3.2 Glucocorticoid
- Page 397 and 398: BNFC 2011-2012 6.3.2 Glucocorticoid
- Page 399 and 400: BNFC 2011-2012 6.4 Sex hormones 377
- Page 401 and 402: BNFC 2011-2012 6.4.2 Male sex hormo
- Page 403 and 404: BNFC 2011-2012 6.4.3 Anabolic stero
- Page 405 and 406: BNFC 2011-2012 6.5.1 Hypothalamic a
- Page 407 and 408: BNFC 2011-2012 6.5.2 Posterior pitu
- Page 409 and 410: BNFC 2011-2012 6.5.2 Posterior pitu
- Page 411 and 412: BNFC 2011-2012 6.6.2 Bisphosphonate
- Page 413 and 414: BNFC 2011-2012 6.7.3 Metyrapone 391
- Page 415 and 416: BNFC 2011-2012 3937 Obstetrics, gyn
- Page 417 and 418: BNFC 2011-2012 7.2.2 Vaginal and vu
- Page 419 and 420:
BNFC 2011-2012 7.3.1 Combined hormo
- Page 421 and 422:
BNFC 2011-2012 7.3.1 Combined hormo
- Page 423 and 424:
BNFC 2011-2012 7.3.1 Combined hormo
- Page 425 and 426:
BNFC 2011-2012 7.3.2 Progestogen-on
- Page 427 and 428:
BNFC 2011-2012 7.3.2 Progestogen-on
- Page 429 and 430:
BNFC 2011-2012 7.3.4 Contraceptive
- Page 431 and 432:
BNFC 2011-2012 7.4 Drugs for genito
- Page 433 and 434:
BNFC 2011-2012 7.4.2 Drugs for urin
- Page 435 and 436:
BNFC 2011-2012 7.4.5 Drugs for erec
- Page 437 and 438:
BNFC 2011-2012 8.1 Cytotoxic drugs
- Page 439 and 440:
BNFC 2011-2012 8.1 Cytotoxic drugs
- Page 441 and 442:
BNFC 2011-2012 8.1.1 Alkylating dru
- Page 443 and 444:
BNFC 2011-2012 8.1.2 Cytotoxic anti
- Page 445 and 446:
BNFC 2011-2012 8.1.3 Antimetabolite
- Page 447 and 448:
BNFC 2011-2012 8.1.3 Antimetabolite
- Page 449 and 450:
BNFC 2011-2012 8.1.5 Other antineop
- Page 451 and 452:
BNFC 2011-2012 8.1.5 Other antineop
- Page 453 and 454:
BNFC 2011-2012 8.2 Drugs affecting
- Page 455 and 456:
BNFC 2011-2012 8.2.2 Corticosteroid
- Page 457 and 458:
BNFC 2011-2012 8.2.2 Corticosteroid
- Page 459 and 460:
BNFC 2011-2012 8.2.2 Corticosteroid
- Page 461 and 462:
BNFC 2011-2012 8.2.4 Other immunomo
- Page 463 and 464:
BNFC 2011-2012 8.2.4 Other immunomo
- Page 465 and 466:
BNFC 2011-2012 9.1.1 Iron-deficienc
- Page 467 and 468:
BNFC 2011-2012 9.1.2 Drugs used in
- Page 469 and 470:
BNFC 2011-2012 9.1.3 Drugs used in
- Page 471 and 472:
BNFC 2011-2012 9.1.3 Drugs used in
- Page 473 and 474:
BNFC 2011-2012 9.1.3 Drugs used in
- Page 475 and 476:
BNFC 2011-2012 9.1.4 Drugs used in
- Page 477 and 478:
BNFC 2011-2012 9.1.6 Drugs used in
- Page 479 and 480:
BNFC 2011-2012 9.2.1 Oral preparati
- Page 481 and 482:
BNFC 2011-2012 9.2.1 Oral preparati
- Page 483 and 484:
BNFC 2011-2012 9.2.2 Parenteral pre
- Page 485 and 486:
BNFC 2011-2012 9.2.2 Parenteral pre
- Page 487 and 488:
BNFC 2011-2012 9.2.2 Parenteral pre
- Page 489 and 490:
BNFC 2011-2012 9.3 Intravenous nutr
- Page 491 and 492:
BNFC 2011-2012 9.4.2 Enteral nutrit
- Page 493 and 494:
BNFC 2011-2012 9.5 Minerals 471dren
- Page 495 and 496:
BNFC 2011-2012 9.5.1 Calcium and ma
- Page 497 and 498:
BNFC 2011-2012 9.5.2 Phosphorus 475
- Page 499 and 500:
BNFC 2011-2012 9.5.3 Fluoride 477Ch
- Page 501 and 502:
BNFC 2011-2012 9.6.2 Vitamin B grou
- Page 503 and 504:
BNFC 2011-2012 9.6.3 Vitamin C 481I
- Page 505 and 506:
BNFC 2011-2012 9.6.4 Vitamin D 483N
- Page 507 and 508:
BNFC 2011-2012 9.6.5 Vitamin E 4851
- Page 509 and 510:
BNFC 2011-2012 9.6.7 Multivitamin p
- Page 511 and 512:
BNFC 2011-2012 9.8.1 Drugs used in
- Page 513 and 514:
BNFC 2011-2012 9.8.1 Drugs used in
- Page 515 and 516:
BNFC 2011-2012 9.8.1 Drugs used in
- Page 517 and 518:
BNFC 2011-2012 9.8.1 Drugs used in
- Page 519 and 520:
BNFC 2011-2012 9.8.2 Acute porphyri
- Page 521 and 522:
BNFC 2011-2012 49910 Musculoskeleta
- Page 523 and 524:
BNFC 2011-2012 10.1.1 Non-steroidal
- Page 525 and 526:
BNFC 2011-2012 10.1.1 Non-steroidal
- Page 527 and 528:
BNFC 2011-2012 10.1.1 Non-steroidal
- Page 529 and 530:
BNFC 2011-2012 10.1.3 Drugs that su
- Page 531 and 532:
BNFC 2011-2012 10.1.3 Drugs that su
- Page 533 and 534:
BNFC 2011-2012 10.1.4 Gout and cyto
- Page 535 and 536:
BNFC 2011-2012 10.2.2 Skeletal musc
- Page 537 and 538:
BNFC 2011-2012 10.2.2 Skeletal musc
- Page 539 and 540:
BNFC 2011-2012 51711 Eye11.1 Admini
- Page 541 and 542:
BNFC 2011-2012 11.3.1 Antibacterial
- Page 543 and 544:
BNFC 2011-2012 11.3.3 Antivirals 52
- Page 545 and 546:
BNFC 2011-2012 11.4.2 Other anti-in
- Page 547 and 548:
BNFC 2011-2012 11.6 Treatment of gl
- Page 549 and 550:
BNFC 2011-2012 11.6 Treatment of gl
- Page 551 and 552:
BNFC 2011-2012 11.7 Local anaesthet
- Page 553 and 554:
BNFC 2011-2012 11.8.1 Tear deficien
- Page 555 and 556:
BNFC 2011-2012 11.9 Contact lenses
- Page 557 and 558:
BNFC 2011-2012 12.1.1 Otitis extern
- Page 559 and 560:
BNFC 2011-2012 12.1.2 Otitis media
- Page 561 and 562:
BNFC 2011-2012 12.2.1 Drugs used in
- Page 563 and 564:
BNFC 2011-2012 12.2.2 Topical nasal
- Page 565 and 566:
BNFC 2011-2012 12.3 Drugs acting on
- Page 567 and 568:
BNFC 2011-2012 12.3.2 Oropharyngeal
- Page 569 and 570:
BNFC 2011-2012 12.3.4 Mouthwashes a
- Page 571 and 572:
BNFC 2011-2012 12.3.5 Treatment of
- Page 573 and 574:
BNFC 2011-2012 13.1.1 Vehicles 551m
- Page 575 and 576:
BNFC 2011-2012 13.2.1 Emollients 55
- Page 577 and 578:
BNFC 2011-2012 13.2.1 Emollients 55
- Page 579 and 580:
BNFC 2011-2012 13.3 Topical antipru
- Page 581 and 582:
BNFC 2011-2012 13.4 Topical cortico
- Page 583 and 584:
BNFC 2011-2012 13.4 Topical cortico
- Page 585 and 586:
BNFC 2011-2012 13.4 Topical cortico
- Page 587 and 588:
BNFC 2011-2012 13.5 Preparations fo
- Page 589 and 590:
BNFC 2011-2012 13.5.2 Preparations
- Page 591 and 592:
BNFC 2011-2012 13.5.2 Preparations
- Page 593 and 594:
BNFC 2011-2012 13.5.2 Preparations
- Page 595 and 596:
BNFC 2011-2012 13.5.3 Drugs affecti
- Page 597 and 598:
BNFC 2011-2012 13.6.1 Topical prepa
- Page 599 and 600:
BNFC 2011-2012 13.6.1 Topical prepa
- Page 601 and 602:
BNFC 2011-2012 13.6.2 Oral preparat
- Page 603 and 604:
BNFC 2011-2012 13.7 Preparations fo
- Page 605 and 606:
BNFC 2011-2012 13.8.2 Camouflagers
- Page 607 and 608:
BNFC 2011-2012 13.10 Anti-infective
- Page 609 and 610:
BNFC 2011-2012 13.10.1 Antibacteria
- Page 611 and 612:
BNFC 2011-2012 13.10.2 Antifungal p
- Page 613 and 614:
BNFC 2011-2012 13.10.3 Antiviral pr
- Page 615 and 616:
BNFC 2011-2012 13.10.5 Preparations
- Page 617 and 618:
BNFC 2011-2012 13.11.2 Chlorhexidin
- Page 619 and 620:
BNFC 2011-2012 13.12 Antiperspirant
- Page 621 and 622:
BNFC 2011-2012 59914 Immunological
- Page 623 and 624:
BNFC 2011-2012 14.1 Active immunity
- Page 625 and 626:
BNFC 2011-2012 14.4 Vaccines and an
- Page 627 and 628:
BNFC 2011-2012 14.4 Vaccines and an
- Page 629 and 630:
BNFC 2011-2012 14.4 Vaccines and an
- Page 631 and 632:
BNFC 2011-2012 14.4 Vaccines and an
- Page 633 and 634:
BNFC 2011-2012 14.4 Vaccines and an
- Page 635 and 636:
BNFC 2011-2012 14.4 Vaccines and an
- Page 637 and 638:
BNFC 2011-2012 14.4 Vaccines and an
- Page 639 and 640:
BNFC 2011-2012 14.4 Vaccines and an
- Page 641 and 642:
BNFC 2011-2012 14.4 Vaccines and an
- Page 643 and 644:
BNFC 2011-2012 14.4 Vaccines and an
- Page 645 and 646:
BNFC 2011-2012 14.5.1 Normal Immuno
- Page 647 and 648:
BNFC 2011-2012 14.5.2 Disease-speci
- Page 649 and 650:
BNFC 2011-2012 14.6 International t
- Page 651 and 652:
BNFC 2011-2012 15.1.1 Intravenous a
- Page 653 and 654:
BNFC 2011-2012 15.1.1 Intravenous a
- Page 655 and 656:
BNFC 2011-2012 15.1.2 Inhalational
- Page 657 and 658:
BNFC 2011-2012 15.1.3 Antimuscarini
- Page 659 and 660:
BNFC 2011-2012 15.1.4 Sedative and
- Page 661 and 662:
BNFC 2011-2012 15.1.4 Sedative and
- Page 663 and 664:
BNFC 2011-2012 15.1.4 Sedative and
- Page 665 and 666:
BNFC 2011-2012 15.1.5 Neuromuscular
- Page 667 and 668:
BNFC 2011-2012 15.1.5 Neuromuscular
- Page 669 and 670:
BNFC 2011-2012 15.1.7 Antagonists f
- Page 671 and 672:
BNFC 2011-2012 15.2 Local anaesthes
- Page 673 and 674:
BNFC 2011-2012 15.2 Local anaesthes
- Page 675 and 676:
BNFC 2011-2012 15.2 Local anaesthes
- Page 677 and 678:
BNFC 2011-2012 655A1InteractionsTwo
- Page 679 and 680:
BNFC 2011-2012 Appendix 1: Interact
- Page 681 and 682:
BNFC 2011-2012 Appendix 1: Interact
- Page 683 and 684:
BNFC 2011-2012 Appendix 1: Interact
- Page 685 and 686:
BNFC 2011-2012 Appendix 1: Interact
- Page 687 and 688:
BNFC 2011-2012 Appendix 1: Interact
- Page 689 and 690:
BNFC 2011-2012 Appendix 1: Interact
- Page 691 and 692:
BNFC 2011-2012 Appendix 1: Interact
- Page 693 and 694:
BNFC 2011-2012 Appendix 1: Interact
- Page 695 and 696:
BNFC 2011-2012 Appendix 1: Interact
- Page 697 and 698:
BNFC 2011-2012 Appendix 1: Interact
- Page 699 and 700:
BNFC 2011-2012 Appendix 1: Interact
- Page 701 and 702:
BNFC 2011-2012 Appendix 1: Interact
- Page 703 and 704:
BNFC 2011-2012 Appendix 1: Interact
- Page 705 and 706:
BNFC 2011-2012 Appendix 1: Interact
- Page 707 and 708:
BNFC 2011-2012 Appendix 1: Interact
- Page 709 and 710:
BNFC 2011-2012 Appendix 1: Interact
- Page 711 and 712:
BNFC 2011-2012 Appendix 1: Interact
- Page 713 and 714:
BNFC 2011-2012 Appendix 1: Interact
- Page 715 and 716:
BNFC 2011-2012 Appendix 1: Interact
- Page 717 and 718:
BNFC 2011-2012 Appendix 1: Interact
- Page 719 and 720:
BNFC 2011-2012 Appendix 1: Interact
- Page 721 and 722:
BNFC 2011-2012 Appendix 1: Interact
- Page 723 and 724:
BNFC 2011-2012 Appendix 1: Interact
- Page 725 and 726:
BNFC 2011-2012 Appendix 1: Interact
- Page 727 and 728:
BNFC 2011-2012 Appendix 1: Interact
- Page 729 and 730:
BNFC 2011-2012 Appendix 1: Interact
- Page 731 and 732:
BNFC 2011-2012 Appendix 1: Interact
- Page 733 and 734:
BNFC 2011-2012 Appendix 1: Interact
- Page 735 and 736:
BNFC 2011-2012 Appendix 1: Interact
- Page 737 and 738:
BNFC 2011-2012 Appendix 1: Interact
- Page 739 and 740:
BNFC 2011-2012 Appendix 1: Interact
- Page 741 and 742:
BNFC 2011-2012 Appendix 1: Interact
- Page 743 and 744:
BNFC 2011-2012 Appendix 1: Interact
- Page 745 and 746:
BNFC 2011-2012 Appendix 1: Interact
- Page 747 and 748:
BNFC 2011-2012 Appendix 1: Interact
- Page 749 and 750:
BNFC 2011-2012 Appendix 1: Interact
- Page 751 and 752:
BNFC 2011-2012 Appendix 1: Interact
- Page 753 and 754:
BNFC 2011-2012 Appendix 1: Interact
- Page 755 and 756:
BNFC 2011-2012 Appendix 1: Interact
- Page 757 and 758:
BNFC 2011-2012 Appendix 1: Interact
- Page 759 and 760:
BNFC 2011-2012 Appendix 1: Interact
- Page 761 and 762:
BNFC 2011-2012 Appendix 1: Interact
- Page 763 and 764:
BNFC 2011-2012 Appendix 1: Interact
- Page 765 and 766:
BNFC 2011-2012 743A2Borderline subs
- Page 767 and 768:
Nutrison c(Nutricia Clinical)Nutris
- Page 769 and 770:
A2.1.2 Enteral feeds (non-disease s
- Page 771 and 772:
A2.1.2.2 Enteral feeds: Less than 1
- Page 773 and 774:
A2.1.3 Enteral feeds (non-disease s
- Page 775 and 776:
Infatrini c(Nutricia Clinical)Nutri
- Page 777 and 778:
Frebini c EnergyDrink(Fresenius Kab
- Page 779 and 780:
A2.2.1.2 Nutritional supplements: M
- Page 781 and 782:
Fortisip c Range(Nutricia Clinical)
- Page 783 and 784:
Forticreme cComplete(Nutricia Clini
- Page 785 and 786:
A2.3 Specialised formulasA2.3.1 Spe
- Page 787 and 788:
Nutramigen c Lipil 2(Mead Johnson)S
- Page 789 and 790:
Specialised formulas: Infant and ch
- Page 791 and 792:
KetoCal c(SHS)Standard dilution(20
- Page 793 and 794:
A2.4 Feed supplementsA2.4.1 High-en
- Page 795 and 796:
Medium-chainTriglyceride (MCT)Oil(S
- Page 797 and 798:
Calshake c(Fresenius Kabi)Powderper
- Page 799 and 800:
BNFC 2011-2012 A2.5 Feed additives
- Page 801 and 802:
BNFC 2011-2012 A2.6.1 Gluten-free f
- Page 803 and 804:
BNFC 2011-2012 A2.7 Nutritional sup
- Page 805 and 806:
BNFC 2011-2012 A2.7 Nutritional sup
- Page 807 and 808:
BNFC 2011-2012 A2.7 Nutritional sup
- Page 809 and 810:
BNFC 2011-2012 A2.7 Nutritional sup
- Page 811 and 812:
BNFC 2011-2012 Appendix 3: Cautiona
- Page 813 and 814:
BNFC 2011-2012 791A4Intravenous inf
- Page 815 and 816:
BNFC 2011-2012 Appendix 4: Intraven
- Page 817 and 818:
BNFC 2011-2012 Dental Practitioners
- Page 819 and 820:
BNFC 2011-2012 Nurse Prescribers’
- Page 821 and 822:
BNFC 2011-2012 799Non-medical presc
- Page 823 and 824:
BNFC 2011-2012 Index of manufacture
- Page 825 and 826:
BNFC 2011-2012 Index of manufacture
- Page 827 and 828:
BNFC 2011-2012 Index of manufacture
- Page 829 and 830:
BNFC 2011-2012 Index of manufacture
- Page 831 and 832:
BNFC 2011-2012 809Special-orderManu
- Page 833 and 834:
BNFC 2011-2012 Abacavir—Alfacalci
- Page 835 and 836:
BNFC 2011-2012 Anthelios—Arthrofe
- Page 837 and 838:
BNFC 2011-2012 Benzodiazepines—Bu
- Page 839 and 840:
BNFC 2011-2012 Cetrimide—Cocaine
- Page 841 and 842:
BNFC 2011-2012 Coumarins—Dermatop
- Page 843 and 844:
BNFC 2011-2012 Disinfectants—Emer
- Page 845 and 846:
BNFC 2011-2012 Eye—Formaldehyde 8
- Page 847 and 848:
BNFC 2011-2012 Glycogen—Homatropi
- Page 849 and 850:
BNFC 2011-2012 Ibuprofen—Iodide 8
- Page 851 and 852:
BNFC 2011-2012 Laxatives—Magnesiu
- Page 853 and 854:
BNFC 2011-2012 Methylenedioxymetham
- Page 855 and 856:
BNFC 2011-2012 Nicardipine—Oftaqu
- Page 857 and 858:
BNFC 2011-2012 Paramax—Plaquenil
- Page 859 and 860:
BNFC 2011-2012 Procarbazine—Regul
- Page 861 and 862:
BNFC 2011-2012 Scottish—Sodium 83
- Page 863 and 864:
BNFC 2011-2012 Syringes—Tocophero
- Page 865 and 866:
BNFC 2011-2012 Ursofalk—Waxsol 84
- Page 869 and 870:
NEWBORN LIFE SUPPORTDry the babyRem
- Page 871 and 872:
PAEDIATRIC ADVANCED LIFE SUPPORTUnr
- Page 873 and 874:
BODY SURFACE AREA IN CHILDRENBody-w
- Page 875 and 876:
Croup(section 3.1)Dexamethasone ora
- Page 877 and 878:
Recommended wording of cautionaryan
Inappropriate
Loading...
Inappropriate
You have already flagged this document.
Thank you, for helping us keep this platform clean.
The editors will have a look at it as soon as possible.
Mail this publication
Loading...
Embed
Loading...
Delete template?
Are you sure you want to delete your template?
DOWNLOAD ePAPER
This ePaper is currently not available for download.
You can find similar magazines on this topic below under ‘Recommendations’.